Company / Free Cash Flow
Decoy Therapeutics Inc. Free Cash Flow History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$10.3M
FY2021
5-year range
-$32.6M / -$10.3M
FY2017-FY2021
Trend
+10.9%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$33M to -$10M over the past 3 years.
Based on SEC 10-K filings.
-$10M in FY2021.
Improved from -$33M to -$10M over the past 3 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, free cash flow increased 10.9% year-over-year.
- Peak free cash flow was recorded in FY2016.
- Lowest free cash flow in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | - | - |
| FY2021 | -$10.3M | +10.9% |
| FY2020 | -$11.6M | - |
| FY2019 | - | - |
| FY2018 | -$32.6M | -55.2% |
| FY2017 | -$21.0M | -220.4% |
| FY2016 | -$6.6M | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026